Isomorphic Labs, the artificial intelligence drug discovery company spun out of Google DeepMind, raised $5 billion in new funding, one of the largest private rounds on record for a drug developer that has yet to test a medicine in people.
The London-based company said Tuesday that Greenoaks and Sequoia Capital co-led the Series C round, with Andreessen Horowitz and several other new investors joining and Alphabet making another significant investment. All existing backers took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund. Isomorphic did not disclose its valuation.
Second big check in six months
The round comes about six months after a $2.1 billion Series B in May and is the first raise since Demis Hassabis stepped back as chief executive of DeepMind to focus on the drug company, which he has led since it was carved out in 2021. Hassabis shared the 2024 Nobel Prize in chemistry for AlphaFold, the DeepMind system that predicts protein structures and underpins much of the Isomorphic platform.
Isomorphic said its drug design engine, a set of simulation models that work across disease areas and types of molecules, is producing positive preclinical results in its own cancer and immunology programs and with partners. It has research deals with Eli Lilly, Novartis and Johnson & Johnson.
Building the clinic
The company said the new money will go toward improving its models, expanding into new areas of biology, and building the translational and clinical development operations it needs to start human trials of its first drug candidates. It has offices in London, Cambridge, Mass., and Lausanne, Switzerland.
Investors have poured a record $23.2 billion into drug discovery startups this year, by one industry tally, as big drugmakers keep buying young biotech companies. Eli Lilly alone has done more than a dozen deals in 2026, most recently agreeing to buy Calytrix Bio for up to $1.5 billion.



